A study of Ripasudil (K-321) eye drops after cataract surgery
The research company Kowa Research Institute, Inc is conducting the clinical trial A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery.
The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
It is planned to include 330 participants.
Actual study start date is August 4, 2022. The researchers expect to complete the study by June 30, 2023.
One primary outcome measure is Safety Assessment, Safety parameters will include monitoring of AEs, TEAEs, safety assessment by slit-lamp biomicroscopy, dilated fundoscopy and IOP.
Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT05528172.
